aldomet
h.a.c. pharma - metildopa (levogira) - metildopa (levogira)
aldomet 250 compresse rivestite con film
future health pharma gmbh - methyldopum anhydricum - compresse rivestite con film - methyldopum anhydricum 250 mg ut methyldopum 283 mg, cellulosi pulvis, acidum citricum, ethylcellulosum, guari gummi, magnesii stearas, silica colloidalis anhydrica, natrii calcii edetas corresp. natrium 0.025 mg, Überzug: acidum citricum monohydricum, hypromellosum, propylenglycolum, talcum, cera carnauba, e 104, e 171, e 172 (rubrum), pro compresso obducto. - hypertonie - synthetika
presinol
bayer s.p.a. - metildopa - metildopa
medopren
malesci istituto farmacobiologico s.p.a. - metildopa (levogira) - metildopa (levogira)
elanpress
recordati industria chimica e farmaceutica s.p.a. - metildopa (levogira) - metildopa (levogira)
vocabria
viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infezioni da hiv - antivirali per uso sistemico - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenti antineoplastici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
livostin augentropfen augentropfensuspension
jntl consumer health ii (switzerland) gmbh - levocabastinum - augentropfensuspension - levocabastinum 0.5 mg ut levocabastini hydrochloridum, propylenglycolum, dinatrii phosphas et natrii dihydrogenophosphas monohydricus corresp. phosphas 9.5 mg, benzalkonii chloridum 0.15 mg, hypromellosum, polysorbatum 80, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - congiuntivite allergica - synthetika
aqua ad iniectabilia sintetica soluzione iniettabile
sintetica sa - aqua ad iniectabile - soluzione iniettabile - aqua ad iniectabile q.s. pro 1 ml. - soluzione vectrice - synthetika
levostab
grunenthal italia s.r.l. - levocabastina - levocabastina